Back to results
US 11,110,171 B2Granted
PD-1 related cancer therapy
AssigneeNew York University
InventorsAdam Mor, Ben Neel
Life of this patent
Estimating the term…
Abstract
Provided are compositions and methods for identifying individuals with cancer who will benefit from PD-1 inhibitor therapy. The method comprises determining levels of signaling lymphocyte activation molecule-associated protein (SAP) in an individual and based on the SAP levels, determining if the individual is suitable for PD-1 inhibitor therapy. Also provided is a method of treatment of X-linked lymphoproliferative disease comprising administering to an individual PD-1 inhibitory therapy, with or without SHP2 inhibitors.
Claims5
A method of treating an individual afflicted with cancer comprising:
- in a sample of blood cells obtained from the individual determining a level of signaling lymphocyte activation molecule-associated protein (SAP) to be lower than a reference SAP level, wherein the reference SAP level is the level of SAP from an individual or individuals without cancer;
- and administering to the individual afflicted with cancer a therapy comprising PD-1 inhibition therapy, and further comprising administering to the individual a SHP2 inhibitor.
Dependencies are inferred from the claim text.